GE Healthcare Acquires Full Stake in Nihon Medi-Physics, Enhancing Radiopharmaceutical Presence in Japan

GE Healthcare has announced the acquisition of Nihon Medi-Physics (NMP), a Tokyo-based radiopharmaceutical company, by purchasing the remaining 50% stake from Sumitomo Chemical[1][2]. This strategic move underscores the critical role Japan plays in the $7 billion global imaging market and is expected to close by March 2025[1][2]. Nihon Medi-Physics, established in 1973, operates 13 manufacturing facilities that produce diagnostic radiopharmaceuticals such as Vizamyl, DaTSCAN, and Myoview, which are vital for neurology, cardiology, and oncology imaging[2]. This acquisition is poised to bolster GE Healthcare’s precision care strategy and strengthen its footprint in Japan’s burgeoning pharmaceutical market[2].